Skip to main content
. 2016 May 28;22(20):4794–4801. doi: 10.3748/wjg.v22.i20.4794

Table 2.

Cancer secondary to immunosuppression

Increased risk under anti-metabolites Increased risk under anti-TNFα Increased risk under anti-metabolite with anti-TNFα
Non-Hodgkin lymphoma[33-35] Melanoma[42] Hepatosplenic T-cell lymphoma[38]
Acute myeloid leukemia and Myelodysplastic syndromes[61]
Non-melanoma skin cancers (basal and squamous cell carcinomas)[39-41]
Urinary tract cancers[62]

TNF-α: Tumor necrosis factor alpha.